Generation of human monocyte-derived DC (MODC) and isolation of primary human DC
PBMC were isolated from buffy coats (provided by the Transfusion Service of the University Medical Center Mainz, Germany) using Biocoll separating solution (density 1,077 g/ml; Merck, Darmstadt, Germany). Cells were washed three times with PBS + 0,5 M EDTA and diluted 9 × 10 6 cells/ml in RPMI 1640 medium plus 1.5% heat-inactivated autologous plasma. Monocytes were enriched by the plastic adherence method [1] . After 45 min incubation at 37° C in a 5% CO 2 incubator nonadherent cells were carefully washed off petri-dishes. The remaining adherent monocytes were cultured in 15 ml X-VIVO 15 (Lonza, Basel, Switzerland) with GM-CSF (800 I.U./ml [Sagramostim] ; Sanofi, Paris, France) and IL-4 (200 I.U./ml; ImmunoTools, Friesoythe, Germany) for five days. One third of medium was replaced every other day (GM-CSF, 800 I.U./ml; IL-4, 200 I.U./ml). On day 6, two thirds of the MODC cultures were harvested and 10 6 cells/well were seeded into 6 well plates. To induce maturation of MODC, fresh media was supplemented with a maturation cocktail composed of IL-4 (200 IU/ml), GM-CSF (400 IU/ml), IL-6 (1000 IU/ml; ImmunoTools), IL-1β (10 ng/ml; Cellgenix, Freiburg, Germany), PGE 2 (1 µg/ml; Tocris, Bristol, UK) and TNF-a (10 ng/ml; Miltenyi, Bergisch Gladbach, Germany) for 48 h. Aliquots were treated with inhibitors as indicated on day 6 of culture.
Primary human DC were purified from PBMC by immunomagnetic sorting using the blood dendrtiic cells isolation kit II (Miltenyi Biotec, Bergisch Graldbach, Germany). Purity of sorted DC was monitored by assessing the frequencies of contaminating CD14 + monocytes and CD19 + B cells by flow cytometry as recommended by the manufacturer, which was regularily below 3%. DC were resuspended in RPMI160 medium supplemented with 1.5% autologous heat-inactivated plasma (10 6 cells/ml) in wells of 96 well plates (100 µl) for subsequent treatment.
Real-time PCR analysis
Total RNA was isolated from MODC using the peqGold Micro RNA kit (S-Line) (vwr, Darmstadt, Germany) and reverse-transcribed by employing the iScript kit (Bio-Rad, Munich, Germany) or All-in-one cDNA Super Mix (Bimake, Houston, USA) as recommended by the manufacturer. Primer pairs used to detect expression of IL-1β (sense: 5ʹ-GGACAAGCTGAGG AAGATGC-3ʹ, anti-sense: 5ʹ-TCGTTATCCCATGTGT CGAA-3ʹ) and the reference gene b2M (sense: 5ʹ-AT GAGTATGCCTGCCGTGTGA-3ʹ, anti-sense: 5ʹ-GGCA TCTTCAAACCTCCATG-3ʹ) were obtained from eurofins MWG Synthesis (Ebersberg, Germany).Relative gene expression was quantified using delta delta CT method.
Flow cytometry
MODC were stained utilizing unlabeled primary antibodies and fluorochrome-conjugated secondary antibodies. The following unlabeled primary antibodies were used: mouse anti-human CD1a (BD, Franklin Lakes, NJ, USA), mouse anti-human CD14 (Beckman Coulter, Brea, CA, USA), mouse anti-human CD80 (Biolegend, San Diego, CA, USA), mouse anti-human CD86 (Hercules, CA, USA) and rat anti-human MHC II HLA-DR antibody (Thermo Fisher Scientific, Waltham, MA, USA). Secondary antibodies used were R-PEconjugated AffiniPure F(ab') 2 Fragment Donkey antimouse IgG (H+L) (Jackson ImmunoResearch, West Grove, PA, USA) and donkey anti-rat IgG (H+L) F(ab') 2 Fragment FITC (Dianova, Hamburg, Germany). Dead cells were excluded by 7-AAD viability staining solution (eBioscience, Waltham, MA, USA). After fixaton with 4 % formaldehyde PBS solution, cells were analyzed on a BD Accuri.
Detection of caspase-1 activity
MODC were harvested on day 6 of culture, and were treated as indicated for 6 h. Caspase-1 activity was detected using the FLICA 660 Caspase-1 Assay Kit (ImmunoChemicals) according to manual, and analyzed on a BD Accuri. 
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